Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese journal of …, 2023 - academic.oup.com
Abstract Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …
被引用次数：2 相关文章
[HTML] nih.gov

[HTML][HTML] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2023 - ncbi.nlm.nih.gov
Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in …

Y Tomita, K Kobayashi, G Kimura, M Oya, H Uemura… - 2023 - pubmed.ncbi.nlm.nih.gov
Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in …

Y Tomita, K Kobayashi, G Kimura… - … Journal of Clinical …, 2023 - search.ebscohost.com
Abstract Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …
[PDF] oup.com

[PDF][PDF] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2023 - academic.oup.com
Abstract Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in …

Y Tomita, K Kobayashi, G Kimura… - Japanese journal of …, 2023 - keio.elsevierpure.com
BACKGROUND: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …
[PDF] researchmap.jp

[PDF][PDF] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2022 - researchmap.jp
Abstract Background: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …
[PDF] archive.org

[PDF][PDF] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2022 - scholar.archive.org
Abstract Background: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …
[PDF] researchgate.net

[PDF][PDF] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2022 - researchgate.net
Abstract Background: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in …

Y Tomita, K Kobayashi, G Kimura, M Oya… - Japanese Journal of …, 2022 - europepmc.org
Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …